Top-line results from the phase III CLARITY study evaluating pimavanserin for the adjunctive treatment of major depressive disorder.-Acadia Pharmaceuticals.
Acadia Pharmaceuticals Inc. announced top-line results from its 298 patient Phase III CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating the efficacy, safety and tolerability of… read more.